To Evaluate the Pharmacokinetics and Safety of Oral Administration of BR9001 Compared With BR900A in Healthy Subjects

Inclusion Criteria: * Adults 19-50 years of age * Body mass index (BMI) ≥ 18.5 and ≤ 27.0 kg/m\^2 at screening * Medically healthy with no clinically significant medical history * No clinically significant result with laboratory test including chemistry, serum, urine test within 3 weeks in prior to administration of investigational product * Understands the study procedures in the Informed consent form (ICF), and be willing and able to comply with the protocol Exclusion Criteria: * History or presence of clinically significant medical or psychiatric condition or disease. * Positive results at screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV). * Creatinint clearance \< 80 mL/min (using Cockcroft-Gault) at screening. * Whole blood donation within a 2 months prior to the first dose of study drug. * Participation in another clinical trial or bioequivalence study within 12 weeks prior to the first dose of study drug(s).